Empowered Funds LLC Buys Shares of 70,253 USANA Health Sciences, Inc. $USNA

Empowered Funds LLC acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 70,253 shares of the company’s stock, valued at approximately $1,500,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in USNA. AQR Capital Management LLC lifted its holdings in shares of USANA Health Sciences by 82.8% in the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company’s stock valued at $589,000 after purchasing an additional 9,894 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of USANA Health Sciences by 31.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company’s stock worth $408,000 after purchasing an additional 3,198 shares in the last quarter. Quantbot Technologies LP increased its stake in shares of USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after purchasing an additional 646 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of USANA Health Sciences during the 2nd quarter worth approximately $422,000. Finally, Jump Financial LLC purchased a new stake in USANA Health Sciences in the 2nd quarter valued at approximately $347,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Stock Performance

USNA stock opened at $14.44 on Friday. The company has a 50 day moving average price of $18.43 and a two-hundred day moving average price of $18.60. The stock has a market capitalization of $266.85 million, a P/E ratio of -11.93, a PEG ratio of 1.60 and a beta of 0.68. USANA Health Sciences, Inc. has a one year low of $12.57 and a one year high of $32.29.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.The business had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Research analysts forecast that USANA Health Sciences, Inc. will post 0.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

USNA has been the subject of several recent research reports. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research downgraded shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Sell rating, According to MarketBeat.com, USANA Health Sciences has an average rating of “Sell”.

Insider Buying and Selling

In related news, insider Brent Neidig sold 5,002 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.82% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.